Rebinyn Approval for Hemophilia B Expanded to Include Routine Prophylaxis
Rebinyn is a recombinant DNA-derived coagulation Factor IX concentrate with an extended half-life.
Bleeding Disorders
Etranacogene Dezaparvovec, a Gene Therapy for Hemophilia B, Gets Priority Review
Etranacogene dezaparvovec is an investigational gene therapy that uses AAV5 to carry the Padua gene variant of factor IX.
Efgartigimod Looks Promising for Primary Immune Thrombocytopenia
The phase 3 ADVANCE trial evaluated the efficacy and safety of efgartigimod in 131 adults with primary ITP.
Apixaban Tied to Lower Risk for Recurrent VTE in Dialysis Population
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
ACC: Bleeding Risk Lower With Tranexamic Acid in Noncardiac Surgery
But, though difference is small, tranexamic acid not noninferior to placebo for primary safety outcome of composite cardiovascular outcome
Gene Therapy Gets Fast Track Status for Hemophilia A
In preclinical studies, ASC618 has been shown to have at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered constructs.
Once-Weekly Efanesoctocog Alfa Prevents Bleeding Episodes in Hemophilia A Trial
The phase 3 XTEND-1 study evaluated efanesoctocog alfa in 159 patients with severe hemophilia A who were previously treated with factor VIII replacement therapy.
Novel Antithrombotic Fast Tracked for Noncardioembolic Ischemic Stroke
The Company is currently evaluating asundexian as monotherapy or in combination with antiplatelet therapy in the PACIFIC phase 2 clinical trial program.
ASA: Less Bleeding Seen With Tenecteplase for Ischemic Stroke
Rate of symptomatic intracranial hemorrhage lower with tenecteplase than the current standard medication for thrombolysis, alteplase
Vonvendi Approved for Severe Type 3 von Willebrand Disease
Results showed the median ABR for all bleeds was reduced by 54.7%.
